IMRT Course 2016

Cohorts 2 and 3: Pelvic/spinal bone sarcomas (33 patients) Does the use of IMRT enable achievement of a radiotherapy treatment plan that delivers the optimal dose while keeping within normal tissue tolerances? Primary endpoint: The proportion of patients where the IMRiS: Intensity Modulated Radiotherapy in Sarcoma Cohort 2 (Ewing’s): Increase proportion of patients receiving 95% of optimal dose from 70% to 90% Cohort 3 (non-Ewing’s): Increase proportion of patients receiving 95% of optimal dose from 0% to 50% Secondary endpoints: Toxicity, response, quality of life, time to local recurrence/disease progression, survival recommended optimal radiotherapy dose can be achieved with IMRT

33